lamivudine has been researched along with Rheumatism in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Long, L; Su, J; Zou, K | 1 |
Balbir-Gurman, A; Braun, M; Braun-Moscovici, Y; Markovits, D; Nahir, MA; Saadi, T | 1 |
Akdogan, A; Bayraktar, Y; Bilgen, SA; Calguneri, M; Ersoy, O; Ertenli, I; Kalyoncu, U; Karadag, O; Kiraz, S; Yonem, O | 1 |
AirĂ², P; Bazzani, C; Frassi, M; Puoti, M; Scarsi, M; Zingarelli, S | 1 |
Li, DJ; Liu, C; Liu, L; Lu, LX; Lu, XJ; Tang, H; Wang, LC; Wang, Y; Xu, KW | 1 |
Chen, CH; Chen, DS; Hsieh, SC; Sheu, JC; Tsai, FC | 1 |
Chng, HH; Chow, WC; Koh, ET; Thong, BY | 1 |
2 review(s) available for lamivudine and Rheumatism
Article | Year |
---|---|
Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reproducibility of Results; Rheumatic Diseases; Risk; Sensitivity and Specificity; Virus Activation | 2018 |
Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Topics: Aged; Antirheumatic Agents; Biological Products; Chronic Disease; Contraindications; Female; Hepatitis B; Hepatitis B virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Premedication; Reverse Transcriptase Inhibitors; Rheumatic Diseases; Tumor Necrosis Factor-alpha; Virus Activation; Virus Replication | 2009 |
1 trial(s) available for lamivudine and Rheumatism
Article | Year |
---|---|
[Effect of Lamivudine on chronic hepatitis B patients with chemotherapy or immunosuppressive agents therapy and research the drug resistance].
Topics: Adult; Antineoplastic Agents; Drug Resistance; Female; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Neoplasms; Reverse Transcriptase Inhibitors; Rheumatic Diseases; Young Adult | 2011 |
4 other study(ies) available for lamivudine and Rheumatism
Article | Year |
---|---|
Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Azathioprine; Cyclophosphamide; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Infliximab; Lamivudine; Male; Methylprednisolone; Middle Aged; Pilot Projects; Rheumatic Diseases | 2016 |
Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.
Topics: Adult; Aged; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Lamivudine; Liver Function Tests; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Reverse Transcriptase Inhibitors; Rheumatic Diseases; Treatment Outcome; Viral Load | 2009 |
Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents.
Topics: DNA, Viral; Fatal Outcome; Female; Hepatitis Antibodies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Function Tests; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rheumatic Diseases; Treatment Outcome; Virus Activation | 2006 |
Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Asian People; Comorbidity; Female; Glucocorticoids; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Lupus Erythematosus, Systemic; Male; Middle Aged; Prednisolone; Retrospective Studies; Rheumatic Diseases; Treatment Outcome; Virus Activation | 2007 |